Additionally, the combination of apatinib and lapatinib (rho = −0.10) or a STING agonist has the potential to significantly enhance sensitivity to apatinib in head and neck squamous cell carcinoma [49]. This evidence concerns the gene STING1 and head and neck squamous cell carcinoma.